Open an Account
search icon
4
NOTIFICATIONS
Best Algo trading app in India
Bigul

BIOCON LTD. - 532523 - Presentation And Video Recording Of Q4 FY22 Earnings Call

 Pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 ('SEBI Listing Regulations'), please find enclosed the presentation on Q4 and full year FY22 Earnings Call conducted today i.e. on 29th April, 2022. The same is also available on the website of the Company www.biocon.com. Further, the Video Recording w.r.t. the Earnings Call is also available on the website of the Company at https://www.biocon.com/news-biocon/video-gallery-biocon/quarterly-statements-biocon/.
29-04-2022

Biocon Biologics expects R&D expenses to hover between 10-15% in the next financial year

 The company said that this will be a significant jump from the R&D spending of Rs 310 crore it reported for FY22, which represented 9 per cent of its revenue for the year.
29-04-2022
Bigul

BIOCON LTD. - 532523 - Format of the Initial Disclosure to be made by an entity identified as a Large Corporate : Annexure A

 Format of Initial Disclosure to be made by an entity identified as a Large Corporate. Sr. No. Particulars Details 1Name of CompayBIOCON LTD. 2CINL24234KA1978PLC003417 3 Outstanding borrowing of company as on 31st March / 31st December, as applicable (in Rs cr) 75.90 4Highest Credit Rating during the previous FY A1+ 4aName of the Credit Rating Agency issuing the Credit Rating mentioned in (4)CRISIL LTD. 5Name of Stock Exchange# in which the fine shall be paid, in case of shortfall in the required borrowing under the frameworkNSE We confirm that we are a Large Corporate as per the applicability criteria given under the SEBI circular SEBI/HO/DDHS/CIR/P/2018/144 dated November 26, 2018. No Name of the Company Secretary: Mayank Verma Designation: Company Secretary EmailId: mayank.verma101@biocon.com Name of the Chief Financial Officer: Indranil Sen Designation: CFO EmailId: co.secretary@biocon.com Date: 29/04/2022 Note: In terms para of 3.2(ii) of the circular, beginning F.Y 2022, in the event of shortfall in the mandatory borrowing through debt securities, a fine of 0.2% of the shortfall shall be levied by Stock Exchanges at the end of the two-year block period. Therefore, an entity identified as LC shall provide, in its initial disclosure for a financial year, the name of Stock Exchange to which it would pay the fine in case of shortfall in the mandatory borrowing through debt markets.
29-04-2022
Bigul

BIOCON LTD. - 532523 - Announcement under Regulation 30 (LODR)-Investor Presentation

 Updated Q4 and full year FY22 Investor Presentation
29-04-2022
Bigul

Earnings Call for Q4FY22 of Biocon Ltd.

 Conference Call with Biocon Management and Analysts on Q4FY22 Performance and Outlook. Listen to the full earnings transcript. Management in attendance: Kiran Mazumdar Shaw and Senior Management Team
29-04-2022
Bigul

Q4FY22 Quarterly Result Announced for Biocon Ltd.

 Biocon declares Q4FY22 result: Biocon Q4FY22 Revenue at Rs 2,476 Cr, Up 21% Core EBITDA at Rs 815 Cr, Up 37% PBT(before Exceptional Items) at Rs 384 Cr, Up 9% Biosimilars Up 48% at Rs 982 Cr Generics Up 26% at Rs 717 Cr Research Services Up 15% at Rs 758 Cr. FY22 Revenue at Rs 8,397 Cr, Up 14% Core EBITDA Up 18% at Rs 2,669 Cr PBT (before Exceptional Item) at Rs 1094 Cr, Up 4% Commenting on the results, Kiran Mazumdar-Shaw, Executive Chairperson, Biocon and Biocon Biologics, said: “FY22 was a transformational year for Biocon. Key strategic moves in our Biosimilars business position us for long-term growth and value creation for our stakeholders. “We believe that the two strategic transactions, with Viatris and Serum Institute Life Sciences, will position Biocon Biologics as a world leading, unique, fully integrated biologics company with a strong differentiated portfolio of biosimilars and vaccines. “We reported a strong consolidated revenue growth of 21% for Q4FY22 at Rs 2,476 Crore driven by 48% growth in Biosimilars, 26% in Generics and 15% in Research Services, businesses. Our Gross R&D; spends increased by 70% this quarter to Rs 232 Crore reflecting our advancing pipeline, that will drive our future growth. Core EBITDA was up by 37% at Rs 815 Crore, representing healthy operating margins of 33%. PBT before Exceptional Items stood at Rs 384 Crore, up by 9%. “On a full- year basis, we delivered consolidated revenue of US$ 1.1 billion (Rs 8,397 Crore) and reported a Core EBITDA growth of 18% at Rs 2,669 Crore with Core EBITDA margins at 32%.” Result PDF
29-04-2022
Bigul

Annual report for Biocon Ltd. for FY-2022
29-04-2022
Bigul

BIOCON LTD. - 532523 - Announcement under Regulation 30 (LODR)-Investor Presentation

 Investor Presentation
28-04-2022
Bigul

BIOCON LTD. - 532523 - Announcement under Regulation 30 (LODR)-Press Release / Media Release

 Press release titled 'Biocon Q4FY22 Revenue at Rs 2,476 Cr, Up 21%; Core EBITDA at Rs 815 Cr, Up 37% ; PBT(before Exceptional Items) at Rs 384 Cr, Up 9%; Biosimilars Up 48% at Rs 982 Cr; Generics Up 26% at Rs 717 Cr; Research Services Up 15% at Rs 758 Cr.'
28-04-2022
Bigul

BIOCON LTD. - 532523 - Corporate Action-Board approves Dividend

 Board approves Dividend
28-04-2022
Next Page
Close

Let's Open Free Demat Account